BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lindahl LM, Besenbacher S, Rittig AH, Celis P, Willerslev-Olsen A, Gjerdrum LMR, Krejsgaard T, Johansen C, Litman T, Woetmann A, Odum N, Iversen L. Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Blood 2018;131:759-70. [PMID: 29208599 DOI: 10.1182/blood-2017-06-788950] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Dong S, Huo H, Mao Y, Li X, Dong L. A risk score model for the prediction of osteosarcoma metastasis. FEBS Open Bio 2019;9:519-26. [PMID: 30868060 DOI: 10.1002/2211-5463.12592] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
2 Chebly A, Chouery E, Ropio J, Kourie HR, Beylot-Barry M, Merlio JP, Tomb R, Chevret E. Diagnosis and treatment of lymphomas in the era of epigenetics. Blood Rev 2021;48:100782. [PMID: 33229141 DOI: 10.1016/j.blre.2020.100782] [Reference Citation Analysis]
3 Manso R, Martínez-Magunacelaya N, Eraña-Tomás I, Monsalvez V, Rodríguez-Peralto JL, Ortiz-Romero PL, Santonja C, Cristóbal I, Piris MA, Rodríguez-Pinilla SM. Mycosis fungoides progression could be regulated by microRNAs. PLoS One 2018;13:e0198477. [PMID: 29894486 DOI: 10.1371/journal.pone.0198477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Walia R, Yeung CCS. An Update on Molecular Biology of Cutaneous T Cell Lymphoma. Front Oncol 2019;9:1558. [PMID: 32039026 DOI: 10.3389/fonc.2019.01558] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
5 Lefrançois P, Xie P, Wang L, Tetzlaff MT, Moreau L, Watters AK, Netchiporouk E, Provost N, Gilbert M, Ni X, Sasseville D, Wheeler DA, Duvic M, Litvinov IV. Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. Oncoimmunology 2018;7:e1467856. [PMID: 30221071 DOI: 10.1080/2162402X.2018.1467856] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
6 Stadler R, Stranzenbach R. Molecular pathogenesis of cutaneous lymphomas. Exp Dermatol 2018;27:1078-83. [DOI: 10.1111/exd.13701] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
7 Wasik MA. Distinct miRNA profile in prognosis of early CTCL. Blood 2018;131:711-711. [DOI: 10.1182/blood-2017-12-821520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Kohnken R, Mishra A. MicroRNAs in Cutaneous T-Cell Lymphoma: The Future of Therapy. J Invest Dermatol 2019;139:528-34. [PMID: 30686578 DOI: 10.1016/j.jid.2018.10.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
9 Phyo ZH, Shanbhag S, Rozati S. Update on Biology of Cutaneous T-Cell Lymphoma. Front Oncol 2020;10:765. [PMID: 32477957 DOI: 10.3389/fonc.2020.00765] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Litman T. Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases. APMIS 2019;127:386-424. [PMID: 31124204 DOI: 10.1111/apm.12934] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
11 Mascolo M, Travaglino A, Varricchio S, Russo D, Sabattini E, Agostinelli C, Bertuzzi C, Baldo A, Pileri A, Picardi M, Pane F, Staibano S. Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides. Virchows Arch 2021;478:961-8. [PMID: 33098490 DOI: 10.1007/s00428-020-02952-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rittig AH, Johansen C, Celis P, Odum N, Litman T, Woetmann A, Lindahl LM, Iversen L. Suppressed microRNA-195-5p expression in mycosis fungoides promotes tumor cell proliferation. Exp Dermatol 2021;30:1141-9. [PMID: 32492224 DOI: 10.1111/exd.14124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Martinez-Escala ME, Choi J. Are MicroRNAs Key to Developing Biomarkers for Cutaneous T-Cell Lymphoma? J Invest Dermatol 2018;138:1906-8. [PMID: 30143078 DOI: 10.1016/j.jid.2018.04.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Hao XY, Li AQ, Shi H, Guo TK, Shen YF, Deng Y, Wang LT, Wang T, Cai H. A novel DNA methylation-based model that effectively predicts prognosis in hepatocellular carcinoma. Biosci Rep 2021;41:BSR20203945. [PMID: 33634306 DOI: 10.1042/BSR20203945] [Reference Citation Analysis]
15 Lin N, Liu Q, Wang M, Wang Q, Zeng K. Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity. PeerJ 2018;6:e5388. [PMID: 30083474 DOI: 10.7717/peerj.5388] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
16 Gluud M, Willerslev-Olsen A, Gjerdrum LMR, Lindahl LM, Buus TB, Andersen MH, Bonefeld CM, Krejsgaard T, Litvinov IV, Iversen L, Becker JC, Persson JL, Koralov SB, Litman T, Geisler C, Woetmann A, Odum N. MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas. Cancers (Basel) 2020;12:E1229. [PMID: 32414221 DOI: 10.3390/cancers12051229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
17 Shen X, Wang B, Li K, Wang L, Zhao X, Xue F, Shi R, Zheng J. MicroRNA Signatures in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma. J Invest Dermatol 2018;138:2024-32. [PMID: 29559342 DOI: 10.1016/j.jid.2018.03.1500] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
18 Sugaya M. Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas. Int J Mol Sci 2021;22:11079. [PMID: 34681738 DOI: 10.3390/ijms222011079] [Reference Citation Analysis]
19 Lai P, Wang Y. Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials. Cancer Biol Med 2021;18:34-51. [PMID: 33628583 DOI: 10.20892/j.issn.2095-3941.2020.0216] [Reference Citation Analysis]
20 Zhang P, Zhang M. Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma. Front Oncol 2021;11:663961. [PMID: 34249700 DOI: 10.3389/fonc.2021.663961] [Reference Citation Analysis]
21 Zhao N, Guo M, Wang K, Zhang C, Liu X. Identification of Pan-Cancer Prognostic Biomarkers Through Integration of Multi-Omics Data. Front Bioeng Biotechnol 2020;8:268. [PMID: 32300588 DOI: 10.3389/fbioe.2020.00268] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
22 Neagu M, Constantin C, Cretoiu SM, Zurac S. miRNAs in the Diagnosis and Prognosis of Skin Cancer. Front Cell Dev Biol 2020;8:71. [PMID: 32185171 DOI: 10.3389/fcell.2020.00071] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 23.0] [Reference Citation Analysis]
23 Li Y, Wang X, Li Y, Ma R, Zhao Z, Ren J, Men J. Early changes in gene expression of the entire pathological process in Cutaneous T-cell lymphoma. J Cell Biochem 2019;120:17472-80. [PMID: 31106473 DOI: 10.1002/jcb.29011] [Reference Citation Analysis]
24 Nordmo C, Glehr G, Altenbuchinger M, Spang R, Ziepert M, Horn H, Staiger AM, Ott G, Schmitz N, Held G, Einsele H, Topp M, Rosenwald A, Rauert-Wunderlich H. Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. Leuk Lymphoma 2021;62:1107-15. [PMID: 33353431 DOI: 10.1080/10428194.2020.1861268] [Reference Citation Analysis]
25 Gambichler T, Salveridou K, Schmitz L, Käfferlein H, Brüning T, Stockfleth E, Sand M, Lang K. Low Drosha protein expression in cutaneous T‐cell lymphoma is associated with worse disease outcome. J Eur Acad Dermatol Venereol 2019;33:1695-9. [DOI: 10.1111/jdv.15652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]